Vaccinex, Inc. (VCNX)
OTCMKTS
· Delayed Price · Currency is USD
0.7879
-0.2121 (-21.21%)
Apr 28, 2025, 12:59 PM EDT
Vaccinex Employees
As of December 31, 2024, Vaccinex had 27 total employees, including 23 full-time and 4 part-time employees. The number of employees decreased by 13 or -32.50% compared to the previous year.
Employees
27
Change (1Y)
-13
Growth (1Y)
-32.50%
Revenue / Employee
$24,040
Profits / Employee
-$745,360
Market Cap
2.41M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
Elite Pharmaceuticals | 64 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Longduoduo Company | 49 |
Vaccinex News
- 7 days ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 7 weeks ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire
- 2 months ago - ARMISTICE CAPITAL, LLC Reduces Stake in Vaccinex Inc: A Strategic Portfolio Adjustment - GuruFocus
- 4 months ago - Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? - Benzinga
- 5 months ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 6 months ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 6 months ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire